Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Enters Into $1.5B Loan Facility

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said last week that it has entered into a 364-day unsecured term loan facility in the principal amount of $1.5 billion.

The company may use the proceeds of the loans to help fund the acquisition of Patheon, which is estimated to be approximately $7.2 billion in total. This includes repayment of Patheon's debt and transaction costs incurred in connection with the acquisition.

The debt facility was established between Thermo Fisher; Bank of America, acting as the administrative agent; the lenders party; and Merrill Lynch, Pierce, Fenner & Smith, who is the sole lead arranger and sole bookrunner, Thermo Fisher said in a document filed with the US Securities and Exchange Commission.

Thermo Fisher announced the Patheon deal in May. It is expected to close around the end of the third quarter of 2017, subject to customary closing conditions.

Also last week, Thermo Fisher priced an offering of $1.5 billion of senior notes, also to fund the acquisition of Patheon.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.